--- title: "Endocrinology Clinical Research Feed | MedicHelpline" specialty: "Endocrinology" specialty_slug: "endocrinology" canonical_url: "https://medichelpline.com/clinical-feed/endocrinology" content_type: "clinical_feed_specialty" page: 1 articles_in_batch: 30 generated_at: "2026-09-05T23:52:17.294Z" license: "CC-BY-NC-4.0 / Informational Use" --- # Endocrinology — Clinical Research Feed ## Specialty Overview: Endocrinology Latest peer-reviewed clinical trials, guidelines, and observational research in **Endocrinology**, indexed and structured for clinical intelligence and AI reasoning. ## Latest Endocrinology Publications ### 1. [Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026.md) - **Source:** Endocrine News | **Published:** 2026-09-04 - **Detail Markdown URL:** [Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026.md) > **Executive GIST:** - This Pharma Friday roundup reports two major FDA actions announced in late August 2026: approval of **Rasonque (daraxonrasib)** for previously treated metastatic pancreatic adenocarcinoma, and approval of **Mounjaro (tirzepatide)** to reduce major adverse cardiovascular events in adults with type 2 diabetes at high CV risk. - Rasonque is a once-daily oral **RAS inhibitor** targeting multiple RAS forms; the approval covers adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or cannot receive multiagent systemic therapy. - In a randomized, open-label multicenter trial of 500 adults with previously treated metastatic pancreatic adenocarcinoma, Rasonque improved median overall survival to 13.2 months versus 6.7 months with standard chemotherapy, per the source. - The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, Priority Review, and reviewed the application under the Commissioner’s National Priority Voucher pilot program; an expanded access protocol had been permitted earlier in May. - Reported common adverse events for Rasonque include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. - On August 28, Eli Lilly announced FDA approval of Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist, to lower the risk of MACE (CV death, nonfatal MI, nonfatal stroke) in adults with type 2 diabetes at high CV risk. - The approval was based on SURPASS-CVOT, the first head-to-head cardiovascular outcomes trial comparing two incretin medicines and the largest tirzepatide study to date, enrolling more than 13,000 participants over 4.5+ years across 30 countries. - In SURPASS-CVOT, Mounjaro demonstrated non-inferiority to **Trulicity (dulaglutide)** with an estimated hazard ratio for time to first MACE of 0.92 (95.3% CI: 0.83, 1.01) and an 8% lower rate of MACE-3 versus dulaglutide. - Safety and tolerability of Mounjaro in the trial were consistent with its established profile; most common adverse events were gastrointestinal, generally mild-to-moderate and occurring during dose escalation. - The roundup quotes FDA and company leaders emphasizing the significance: Rasonque fills a major unmet need in metastatic pancreatic adenocarcinoma and the Mounjaro approval addresses cardiovascular risk in type 2 diabetes while building on its glucose- and weight-related benefits. ### 2. [Endocrine Society Launches Center on Obesity and Unveils Scientific Statement on Obesity Medicines](https://medichelpline.com/clinical-feed/endocrine-news-1-experts-to-debut-society-s-center-on-obesity-and-new-scientific-statement.md) - **Source:** Endocrine News | **Published:** 2026-09-04 - **Detail Markdown URL:** [Endocrine Society Launches Center on Obesity and Unveils Scientific Statement on Obesity Medicines](https://medichelpline.com/clinical-feed/endocrine-news-1-experts-to-debut-society-s-center-on-obesity-and-new-scientific-statement.md) > **Executive GIST:** - The Endocrine Society will introduce its new **Center on Obesity** and release a Scientific Statement titled “Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines” at a member-only virtual event on September 9. - Daniel J. Drucker, MD, leader of the writing group and a pioneer in GLP-1 receptor agonist therapies, will present the statement’s principal findings. - Amy E. Rothberg, MD, Chair of the Society’s Obesity Task Force, will describe how the Center will support obesity care and research. Mehmet Furkhan Burak, MD, Obesity Special Interest Group Co-Chair, will emcee. - The Scientific Statement was developed by eight experts who reviewed more than 200 studies to assess evolving obesity treatments, current evidence, and remaining questions. - The Center aims to leverage members’ expertise in hormonal causes and treatments of obesity to accelerate scientific understanding and advance treatments for people with obesity worldwide. - The virtual event agenda will address implications of the new science for patients and practice; expansion of obesity treatment options with injectable and oral **GLP-1–based medications**; emerging treatments and new research directions; heterogeneity in patient responses and treatment effectiveness; gaps in obesity biology and energy homeostasis research; evaluation of treatment success beyond total body weight loss; and efforts to improve obesity diagnosis and access to care. - Members can register to attend the event, which is scheduled for 11 AM to 12 PM ET on Wednesday, September 9. Details beyond those reported in the source were not provided. ### 3. [Using Mendelian randomisation with RCTs to estimate long-term effects of dietary interventions](https://medichelpline.com/clinical-feed/medrxiv-2-connecting-diet-and-disease-using-mendelian-randomisation-to-bridge-the-gap.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [Using Mendelian randomisation with RCTs to estimate long-term effects of dietary interventions](https://medichelpline.com/clinical-feed/medrxiv-2-connecting-diet-and-disease-using-mendelian-randomisation-to-bridge-the-gap.md) > **Executive GIST:** - Establishing causal links between **diet** and disease is difficult because long-term randomized controlled trials (RCTs) with disease endpoints are often impractical. Short-term RCTs can detect intermediate molecular traits that change with an intervention. - **Mendelian randomisation (MR)** leverages genetic variants as proxies for modifiable exposures to estimate effects of lifelong differences in those exposures on disease risk, but is limited for complex dietary patterns because genetic instruments more often index biological mechanisms than specific foods or diets. - The authors propose a two-step framework that integrates **dietary RCTs** with MR: (1) use RCT data to identify molecular or intermediate traits altered by a dietary intervention; (2) use MR to test whether those altered traits are causally associated with long-term disease risk. - The framework was illustrated using the Diabetes Remission Clinical Trial (**DiRECT**). DiRECT protein measurements identified 216 of 4,601 circulating proteins that changed after the intervention (step 1). - In step 2, MR analyses found 10 of those proteins to be associated with diabetes risk. Comparison of the MR-derived estimates with observed protein–remission associations from DiRECT showed broad agreement (correlation r ≈ −0.645; R2 = 0.416), supporting the framework’s utility. - The authors make code available on GitHub for reproducibility; the underlying study data are not publicly available. Ethical approval for the trial was obtained from the West of Scotland Research Ethics Committee (13/WS/0314). - The approach aims to bridge short-term mechanistic RCT evidence and potential lifetime risk effects, acknowledging MR’s limitations for whole-diet exposures and highlighting how molecular intermediates can link diet interventions to disease outcomes. ### 4. [AI-Based Early Detection of Polycystic Ovary Syndrome Using Follicle Count and Machine Learning](https://medichelpline.com/clinical-feed/medrxiv-0-ai-driven-early-detection-of-polycystic-ovary-syndrome-via-follicle-count.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [AI-Based Early Detection of Polycystic Ovary Syndrome Using Follicle Count and Machine Learning](https://medichelpline.com/clinical-feed/medrxiv-0-ai-driven-early-detection-of-polycystic-ovary-syndrome-via-follicle-count.md) > **Executive GIST:** - The study addresses underdiagnosis and delayed diagnosis of **Polycystic Ovary Syndrome** (PCOS) by developing machine learning models for early prediction using clinical data. - Researchers used a structured dataset of 542 patient records and 42 features, including anthropometrics, hormone levels, and **follicle count** among other clinical and symptom indicators. - Data preprocessing included cleaning, scaling/normalization, and correlation-based feature selection to retain the most predictive variables and prevent dominance by large-range features. - Multiple classification algorithms were trained and compared: Logistic Regression, Decision Tree, K-nearest neighbors (KNN), and **Random Forest**. - The Random Forest model delivered the best overall performance, with reported accuracy of approximately 88%, indicating ensemble models can capture non-linear interactions in clinical data. - The authors situate results alongside international clinical guidance and recent literature on explainable and clinically applicable PCOS prediction systems, emphasizing the need for clinical interpretability. - The dataset originates from a publicly distributed PCOS benchmarking dataset (542 records) with mixed continuous and categorical features, and the target label indicates PCOS status (Y/N). - The paper is a medRxiv preprint and has not undergone peer review; the authors note ethical approvals and participant consent were obtained and disclose no competing interests. - Data availability is described: the dataset includes BMI, hormone concentrations, follicle counts, symptom indicators (acne/hirsutism), cycle regularity, and lifestyle features obtained from a commonly used research dataset. - The study highlights potential for machine learning to support earlier identification of PCOS but does not provide peer-reviewed clinical practice recommendations; further validation and explainability work are implied as next steps. ### 5. [Casp1 and Ripk3 jointly support homeostatic insulin secretion in mice](https://medichelpline.com/clinical-feed/biorxiv-8-casp1-and-ripk3-are-required-for-homeostatic-insulin-secretion-in-mice.md) - **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [Casp1 and Ripk3 jointly support homeostatic insulin secretion in mice](https://medichelpline.com/clinical-feed/biorxiv-8-casp1-and-ripk3-are-required-for-homeostatic-insulin-secretion-in-mice.md) > **Executive GIST:** - The study tested metabolic effects of deleting or inhibiting **Casp1** and **Ripk3** alone and together in mice fed a matched low-fat or a 60% kcal high‑fat diet. - Mouse genotypes included wild-type (WT), Casp1/11 knockout (KO), Ripk3 KO and Casp1/11/Ripk3 double knockout (DKO); both sexes were studied. - High‑fat feeding increased adiposity in male but not female mice across single and double KO genotypes and produced impaired glucose tolerance and insulin sensitivity markers. - In mice fed a low‑fat diet, dual loss or pharmacological inhibition of **Casp1** and **Ripk3** reduced glucose excursion after glucose challenge because of increased plasma **insulin** levels. - Increased glucose‑stimulated insulin secretion was reproduced ex vivo in isolated islets from DKO mice and with pharmacologic inhibitors in WT islets, indicating an islet‑intrinsic effect. - Islet cellular composition (proportions of α-, β-, and δ-cells) was not altered in DKO mice, indicating increased insulin release was independent of major changes in cell fractions. - DKO islets showed a reduction in urocortin‑3 (Ucn3)-positive β‑cells compared to controls, implicating altered Ucn3–somatostatin (Sst) signaling; however, only exogenous somatostatin (octreotide), not Ucn3, normalized the decreased glucose excursion in vivo. - The authors conclude endogenous **Casp1** and **Ripk3** coordinate normal glucose‑stimulated insulin release independent of their canonical roles in inflammation or programmed cell death. - The source did not report detailed statistical values, effect sizes, or full mechanistic pathways; those details were not provided in the preprint abstract and main text excerpt. ### 6. [Endocrine Society Launches Center on Obesity and New Scientific Statement on Obesity Medicines](https://medichelpline.com/clinical-feed/endocrine-news-0-new-offerings-demonstrate-the-endocrine-society-s-leadership-role-in-obesity.md) - **Source:** Endocrine News | **Published:** 2026-09-04 - **Detail Markdown URL:** [Endocrine Society Launches Center on Obesity and New Scientific Statement on Obesity Medicines](https://medichelpline.com/clinical-feed/endocrine-news-0-new-offerings-demonstrate-the-endocrine-society-s-leadership-role-in-obesity.md) > **Executive GIST:** - Rising global **obesity** rates are prompting clinicians, researchers, public health authorities, payers, and the public to seek solutions to the disease’s health, economic, and societal impacts. - Endocrinologists and endocrine researchers have been central to obesity advances, including discovery and study of **GLP-1 receptor agonists**, described as highly effective treatments for one in eight people worldwide with obesity. - The Endocrine Society launched a new **Center on Obesity** to centralize resources for research, treatment, education, advocacy, and member engagement. - The Center’s digital hub will host the Society’s new **Scientific Statement**, a soon-to-be-updated **Clinical Practice Guideline**, meetings, webinars, funding opportunities, journal research highlights, news, videos, and advocacy initiatives focused on improving access to anti-obesity medications and research funding. - The Society published a Scientific Statement titled “Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines,” developed by a panel led by Daniel Drucker, MD, that examined more than 200 studies. - The Scientific Statement highlights progress since GLP-1 receptor agonists, identifies research opportunities, discusses measurement of treatment success beyond total body weight loss, and supports advocacy for research funding and evidence-based obesity policy. - The Endocrine Society’s ongoing activities include an Obesity Special Interest Group, journals and meetings featuring obesity research, continuing education through the **Center for Learning** and the Obesity Fellows Conference, and advocacy such as urging Congress to provide permanent coverage for newer effective medications. - The Society plans to expand Center resources in response to discussions from the Obesity Special Interest Group and events like Clinical Endocrinology Update 2026 and the Obesity Fellows Program, and to disseminate those resources via newsletters, social media, and EndoForum. - The Center on Obesity and Scientific Statement together reflect the Endocrine Society’s organizational prioritization of obesity as a core pillar and its commitment to advancing clinical care, research, and policy related to obesity. ### 7. [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md) - **Source:** BMJ Open | **Published:** 2026-09-04 - **Detail Markdown URL:** [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md) > **Executive GIST:** - The North West London Diabetes Cohort (NWLDC) is an electronic health record (EHR) resource designed to characterise a large diabetes population to support complications research and prognostic modelling. - At baseline the cohort includes 337,271 patients with diabetes: 279,067 with **type 2 diabetes**, 17,638 with type 1 diabetes, 33,590 with gestational diabetes and 6,916 with unspecified diabetes. - Earliest recorded diabetes diagnosis in the data is January 1932; records were current to 27 May 2025. - The cohort contains comprehensive demographic data (age, sex, Deprivation Index, ethnicity) and clinical measures (glycated haemoglobin, BMI, blood pressure, lipids, estimated glomerular filtration rate). - Fourteen major diabetes complications are tracked longitudinally across the population. - Among patients with type 2 diabetes, incidence rates per 1,000 person-years reported include **diabetic retinopathy** 74.6, hypertension 51.0 and kidney disease 31.4. - Cumulative incidence analyses used the **Aalen-Johansen** estimator to account for mortality as a competing risk. - Analyses revealed significant ethnic disparities: Black, Asian, mixed and other ethnic groups had higher risks of complications compared with White patients. - Time-varying Cox models showed strong clustering between cardiovascular and renal complications, described as a **cardiometabolic-renal syndrome**. - Mental health conditions (depression and anxiety) were common and appeared both before and after diabetes diagnosis. - Future planned work will develop and validate prognostic models, incorporate medication data to refine diabetes type classification, assess antidiabetic medication effectiveness for preventing complications, and examine demographic differences in model performance. - Additional planned EHR interrogation will assess lifestyle-related recording such as dietary advice, referrals to weight management and alcohol consumption coding. ### 8. [INSULIN Act: Bipartisan House Bill to Cap Insulin Cost and Improve Access](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-applauds-introduction-of-bipartisan-bill-to-address-insulin.md) - **Source:** Endocrine News | **Published:** 2026-09-03 - **Detail Markdown URL:** [INSULIN Act: Bipartisan House Bill to Cap Insulin Cost and Improve Access](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-applauds-introduction-of-bipartisan-bill-to-address-insulin.md) > **Executive GIST:** - The Endocrine Society publicly applauded the introduction of the bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (**INSULIN Act**) in the House of Representatives on September 3, 2026. - The bill was introduced by Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Kim Schrier (D-WA), Rob Bresnahan (R-PA), and Angie Craig (D-MN). - Key provisions include capping out-of-pocket insulin costs at **$35 per month** for people with private insurance, establishing a resource center and hotline for uninsured patients, and promoting biosimilar competition to lower prices. - The Endocrine Society emphasized that **insulin affordability** is life‑or‑death for many people with diabetes and endorsed the bill as a step to ensure access to lifesaving medication. - The Society quoted Robert W. Lash, MD, its Chief Medical Officer, repeating support for the sponsors and restating that the bill would help people with private insurance and connect uninsured patients to resources. - The INSULIN Act aligns with the Society’s Insulin Access and Affordability Position Statement, which recommends limiting insulin co-pays to no more than **$35 per month**. - The article cites CDC estimates that 38.4 million people (11.6% of the U.S. population) have diabetes and that in 2021 nearly one in five American adults with diabetes—about 1.3 million people—rationed their insulin. - The Endocrine Society stated it will work with both the House and Senate to advance access to affordable insulin for all people with diabetes. - The source did not report detailed legislative text, implementation timelines, committee referrals, or projected fiscal impacts of the INSULIN Act. ### 9. [Bradley David Anawalt, MD: 2026 Outstanding Educator Laureate on Teaching and Andrology](https://medichelpline.com/clinical-feed/endocrine-news-1-sharing-the-joy-excitement-and-enthusiasm-q-a-with-bradley-david-anawalt-md.md) - **Source:** Endocrine News | **Published:** 2026-09-03 - **Detail Markdown URL:** [Bradley David Anawalt, MD: 2026 Outstanding Educator Laureate on Teaching and Andrology](https://medichelpline.com/clinical-feed/endocrine-news-1-sharing-the-joy-excitement-and-enthusiasm-q-a-with-bradley-david-anawalt-md.md) > **Executive GIST:** - Bradley David Anawalt, MD, professor and vice chair in the Department of Medicine at the University of Washington, received the Endocrine Society’s 2026 Outstanding Educator Laureate Award in recognition of sustained contributions to medical education. - He has been a long-time participant and presenter at **ENDO**, attending annually since 1992 and frequently delivering both teaching and research presentations. - Anawalt is an internationally recognized expert in **andrology** and the diagnosis and treatment of **male hypogonadism**, and he has led research in male hormonal contraception. - His work in male contraceptive trials involved hundreds of enthusiastic research participants and contributed to expanded knowledge of male reproductive endocrinology, infertility, and hypogonadism management. - He traces his interest in endocrinology to formative courses in biochemistry and mentorship during medical school; a key turning point was joining research on male hormonal contraception under Bill Bremner at the VA. - Central to his teaching philosophy is adapting content to the audience: he emphasizes understanding learners’ backgrounds and tailoring talks differently for undergraduates, residents, fellows, faculty, or nonclinical audiences. - Anawalt attributes his teaching style to a series of mentors who modeled curiosity, enthusiasm, and joy for learning; one repeated mantra he recalls is “repetition is the mother of learning.” - He encourages saying “yes” to teaching opportunities early in a career to gain experience and to learn how to modify presentations for different audiences. - Outside medicine, Anawalt balances work with regular exercise—running, biking, hiking—and varied cultural interests including reading and music; upcoming personal trips mentioned include hikes in the Grand Canyon and the Scottish Highland Trail. - The interview underscores that his educational contributions communicate factual material while fostering collegiality and a lasting joy of learning among students, aligning with the reasons cited for the Laureate honor. ### 10. [Scalable Biological Clock for Metabolic Disease Prediction Using the Phenome India Cohort](https://medichelpline.com/clinical-feed/medrxiv-8-a-scalable-biological-clock-for-metabolic-disease-prediction-from-the-phenome.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-03 - **Detail Markdown URL:** [Scalable Biological Clock for Metabolic Disease Prediction Using the Phenome India Cohort](https://medichelpline.com/clinical-feed/medrxiv-8-a-scalable-biological-clock-for-metabolic-disease-prediction-from-the-phenome.md) > **Executive GIST:** - The document is a medRxiv preprint titled “A Scalable Biological Clock for Metabolic Disease Prediction from the Phenome India Cohort.” - The preprint lists a large multi‑institutional author group including the Phenome India Consortium and provides a DOI: https://doi.org/10.64898/2026.08.29.26361656. - Authors and affiliations span multiple Indian research institutions, including Ashoka University, CSIR‑Institute of Genomics and Integrative Biology, CSIR‑Centre for Cellular and Molecular Biology, CSIR‑National Chemical Laboratory, and other CSIR centers. - The article is explicitly identified as a **preprint** and has not been peer reviewed; the source cautions it should not be used to guide clinical practice. - The title indicates the study developed a **scalable biological clock** aimed at **metabolic disease prediction** using data from the **Phenome India Cohort**. - The provided source content contains only metadata (title, author list, affiliations, DOI) and site navigation; the manuscript text, abstract, methods, results, and conclusions were not included in the supplied material. - Because the supplied source text lacks study details, sample size, model design, features, performance metrics, validation, and recommendations were not reported and cannot be summarized or inferred. - Key topical terms present in the source are **biological clock**, **metabolic disease prediction**, **Phenome India Cohort**, and **preprint**; no additional outcome data or methodological specifics are available in the supplied content. ### 11. [Mitochondrial transfer between pancreatic beta cells and islet macrophages mediates metabolic cros](https://medichelpline.com/clinical-feed/biorxiv-19-mitochondrial-transfer-mediates-metabolic-communication-between-beta-cells-and.md) - **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-03 - **Detail Markdown URL:** [Mitochondrial transfer between pancreatic beta cells and islet macrophages mediates metabolic cros](https://medichelpline.com/clinical-feed/biorxiv-19-mitochondrial-transfer-mediates-metabolic-communication-between-beta-cells-and.md) > **Executive GIST:** - The study used mice with beta cell–specific expression of mitochondrial GFP (PhAMfloxIns1Cre) to test whether **mitochondrial transfer** occurs from **beta cells** to **islet macrophages**. - The authors report that beta cells transfer mitochondria to islet macrophages both **in vivo** and **in vitro**, demonstrating an intercellular route of metabolic communication within pancreatic islets. - Exposure to diabetogenic stressors did not change the observed frequency of mitochondrial transfer, indicating transfer persists under stress conditions described in the source. - Macrophages that contained beta cell–derived GFP-labelled mitochondria showed increased rates of protein synthesis relative to macrophages without transferred mitochondria. - Bulk RNA-sequencing of macrophages that received beta cell–derived mitochondria identified upregulation of activity-regulated cytoskeleton associated protein (**Arc**). - Pharmacologic or experimental disruption of **actin cytoskeleton** dynamics prevented mitochondrial transfer, implicating actin-dependent processes in the transfer mechanism. - The authors propose that mitochondrial transfer is a previously unrecognized mechanism of beta cell–macrophage communication that may contribute to islet homeostasis and immune regulation. - Study metadata: preprint posted September 3, 2026, on bioRxiv; corresponding author contact and author list reported. Competing interest: one author (CBV) disclosed roles with Integrated Nanotherapeutics. Funders include Breakthrough T1D, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Michael Smith Health Research BC. - The source did not report quantitative frequencies, detailed transfer kinetics, specific diabetogenic stressors used, or downstream functional consequences beyond protein synthesis and Arc upregulation. ### 12. [Testosterone and Atrial Fibrillation Risk: U-Shaped Relationship and Clinical Implications](https://medichelpline.com/clinical-feed/endocrine-news-0-men-with-low-or-high-testosterone-may-have-higher-risk-of-irregular-heartbeat.md) - **Source:** Endocrine News | **Published:** 2026-09-02 - **Detail Markdown URL:** [Testosterone and Atrial Fibrillation Risk: U-Shaped Relationship and Clinical Implications](https://medichelpline.com/clinical-feed/endocrine-news-0-men-with-low-or-high-testosterone-may-have-higher-risk-of-irregular-heartbeat.md) > **Executive GIST:** - A narrative review published in the Journal of the Endocrine Society evaluated links between **testosterone** levels, testosterone replacement therapy, and risk of **atrial fibrillation (AF)** in men. - The review concludes evidence is consistent with a U-shaped relationship: both low and high total testosterone levels are associated with increased AF risk, while mid-range values show the lowest risk. - Support for the U-shaped pattern comes from large population studies and laboratory work reported since 2025 showing distinct cellular mechanisms by which low and high testosterone can alter cardiac cells. - For men receiving **testosterone replacement therapy (TRT)**, authors recommend aiming to restore total testosterone to the middle of the normal range (approximately 350–550 ng/dL) rather than driving levels to the high end; this therapeutic range is inferred from observational data and has not been prospectively tested. - Clinical suggestions to personalize TRT include using calculated free testosterone when SHBG is abnormal, favoring steady-release formulations over short-acting ones in men with cardiovascular or arrhythmic risk, and maintaining normal hematocrit as the principal dose-limiting safety constraint. - The review advises pre-treatment risk stratification and addressing modifiable contributors to AF risk such as obesity, sleep apnea, hypertension, and alcohol use. - Monitoring recommendations while on TRT include rhythm surveillance, hematocrit checks, blood pressure measurement, and renal and hepatic function testing. - The authors emphasize that the article is a narrative synthesis of existing literature rather than a meta-analysis, and its conclusions are interpretive rather than definitive. - The overall message is that **individualized treatment and structured monitoring** are necessary when prescribing TRT because both insufficient and excessive testosterone may increase AF risk. ### 13. [Cinnamon Supplementation Plus Exercise in Overweight Women: Effects on Body Circumference and Sex](https://medichelpline.com/clinical-feed/pubmed-42683508.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-02 | DOI: [10.1080/15502783.2026.2724102](https://doi.org/10.1080%2F15502783.2026.2724102) - **Detail Markdown URL:** [Cinnamon Supplementation Plus Exercise in Overweight Women: Effects on Body Circumference and Sex](https://medichelpline.com/clinical-feed/pubmed-42683508.md) > **Executive GIST:** - Study population: 26 inactive overweight and obese women randomized into two equal groups (exercise alone, exercise plus cinnamon). Four-week intervention with exercise sessions three times weekly; the supplementation group also received cinnamon three times weekly. Both chest and abdominal circumference and serum sex hormones were measured before and after the intervention. - Anthropometry outcomes: Both groups experienced significant pre-to-post reductions in **chest circumference** and **abdominal circumference** (all p ≤ 0.005). Between-group comparison showed a significant difference only for chest circumference (p = 0.003), favoring one group, while abdominal circumference changes did not differ between groups (p > 0.05). - Reproductive hormone outcomes: **Estradiol**, **progesterone**, and **follicle-stimulating hormone (FSH)** increased significantly from baseline in both groups (all p ≤ 0.005). **Luteinizing hormone (LH)** decreased significantly in both groups (all p ≤ 0.005). There were no significant between-group differences for any reproductive hormone (all p > 0.05). - Interpretation: Exercise training over 4 weeks was associated with favorable changes in chest and abdominal circumferences and in circulating sex hormones among overweight and obese women. Adding cinnamon supplementation produced a statistically significant additional change only in chest circumference; it did not produce additional benefits for abdominal circumference or reproductive hormone profiles compared with exercise alone. - Study design and context: Randomized controlled trial; short duration (4 weeks); small sample size (n = 26). Authors note that findings require confirmation in larger, adequately powered trials. - Keywords and focus: **cinnamon**, **exercise**, **abdominal circumference**, **chest circumference**, **sex hormones**, **obesity**, **overweight**. ### 14. [Semaglutide Associated With Lower Bone Fracture Risk in Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-video-semaglutide-linked-to-lower-bone-fracture-risk.md) - **Source:** Endocrine News | **Published:** 2026-09-02 - **Detail Markdown URL:** [Semaglutide Associated With Lower Bone Fracture Risk in Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-video-semaglutide-linked-to-lower-bone-fracture-risk.md) > **Executive GIST:** - Researchers presenting at ENDO 2026 reported that people with **type 2 diabetes** treated with **semaglutide** had fewer bone fractures than patients receiving other anti‑obesity therapies. - The analysis used the Atropos Health Eos electronic health record dataset covering roughly **161 million** U.S. patients from January 2016 to December 2023. - The retrospective cohort included adults (≥18 years) with type 2 diabetes, no prior fractures, and no use of osteoporosis medications. - The semaglutide treatment group numbered **26,324**; the control group receiving dulaglutide, phentermine/topiramate, or bupropion/naltrexone numbered **33,555**. - The semaglutide cohort experienced **794** fractures versus **1,045** fractures in the control cohort. - Semaglutide was also associated with a greater reduction in **BMI** compared with the control group. - Investigators noted prior literature showing rapid weight loss from **GLP‑1** medications can lead to bone thinning and fractures, while slower or moderate weight loss may preserve bone mass. - Study authors, including Jairo Noreña, MD, and Sun Kim, MD, MS, emphasized this work is an early step and called for prospective studies to confirm bone‑protective effects of semaglutide. - The team highlighted clinical relevance because bone fractures increase pain, cost, and reduce quality of life, especially with aging, and recommended monitoring bone health during weight‑loss programs. - The report was presented as an abstract at ENDO 2026 and summarized in a video interview; authors recommend further prospective research to confirm findings. ### 15. [Yoga-Based Lifestyle Intervention to Improve Endothelial Function in Type 2 Diabetes: Protocol of](https://medichelpline.com/clinical-feed/bmj-open-17-effect-of-yoga-based-lifestyle-intervention-on-endothelial-function-and.md) - **Source:** BMJ Open | **Published:** 2026-09-02 - **Detail Markdown URL:** [Yoga-Based Lifestyle Intervention to Improve Endothelial Function in Type 2 Diabetes: Protocol of](https://medichelpline.com/clinical-feed/bmj-open-17-effect-of-yoga-based-lifestyle-intervention-on-endothelial-function-and.md) > **Executive GIST:** - This protocol describes the Yoga V-AgE trial, a randomised, open-label, blinded end-point study assessing a structured **yoga-based lifestyle** programme in adults with **type 2 diabetes (T2DM)**. - The rationale is that cardiovascular disease remains the leading cause of morbidity and mortality in T2DM, with residual risk despite optimal glycaemic control; targeting vascular mechanisms such as **endothelial dysfunction** is therefore important. - The trial will enrol 248 adults aged 30–70 years with T2DM diagnosed for at least one year, randomised equally into four parallel arms (three intervention variants plus standard care control). - Interventions: three different components of the yoga-based lifestyle programme delivered in addition to standard medical care; control receives standard medical care alone. Intervention duration is 12 weeks with supervised sessions twice weekly plus guided home practice. - Primary outcome: change in endothelial function measured by **flow-mediated dilatation (FMD)**. Secondary outcomes: arterial stiffness, vascular ageing markers, glycaemic and lipid profiles, autonomic function, oxidative stress, quality of life, and cost of care. - Outcomes assessed at baseline, 3, 6 and 12 months; outcome assessors are blinded to group allocation. Analyses follow intention-to-treat with ANCOVA and mixed-effects models; effect estimates with 95% CIs will be reported and sensitivity analyses performed. - Mechanistic assessments will examine autonomic, inflammatory, oxidative and metabolic pathways to elucidate potential modes of action. - Ethics approval was obtained from the Institutional Ethics Committee of SDM College of Medical Sciences and Hospital (approval no. SDMIEC/2025/1075). Trial registration: CTRI/2024/10/075712. - Planned dissemination includes peer-reviewed publications, conference presentations and stakeholder meetings to inform integrative strategies for preventing cardiovascular complications in T2DM. ### 16. [Medial Plantar Nerve Shear Wave Elastography and Viscosity for Grading Diabetic Peripheral Neuropa](https://medichelpline.com/clinical-feed/medrxiv-7-medial-plantar-nerve-shear-wave-elastography-and-viscosity-imaging-for.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Medial Plantar Nerve Shear Wave Elastography and Viscosity for Grading Diabetic Peripheral Neuropa](https://medichelpline.com/clinical-feed/medrxiv-7-medial-plantar-nerve-shear-wave-elastography-and-viscosity-imaging-for.md) > **Executive GIST:** - Study evaluated whether **medial plantar nerve** shear wave speed (Cs) and viscosity coefficient (Vi) correlate with diabetic peripheral neuropathy (DPN) severity and distinguish adjacent clinical categories. - 113 patients with type 2 diabetes were grouped by Toronto Clinical Scoring System (TCSS) into non-DPN (n = 33), mild DPN (n = 46), and moderate DPN (n = 34). - **Shear wave elastography** measured Cs and viscosity imaging measured Vi of the medial plantar nerve in all participants. - Both Cs and Vi showed progressive increases across non-DPN, mild DPN, and moderate DPN (P < 0.001), indicating rising viscoelasticity with greater neuropathy severity. - Receiver operating characteristic (ROC) analyses assessed discrimination for adjacent group comparisons: non-DPN vs mild DPN and mild vs moderate DPN. - For non-DPN versus mild DPN, AUCs were 0.688 for Cs, 0.741 for Vi, and 0.745 for their combined logistic model; pairwise differences were not statistically significant. - For mild versus moderate DPN, AUCs were 0.707 for Cs, 0.794 for Vi, and 0.799 for the combined model; the combined model significantly outperformed Cs alone (P = 0.045). - No significant difference was observed between Cs and Vi, nor between Vi and the combined model for mild versus moderate DPN (P = 0.162 and 1.000, respectively). - Authors conclude that quantitative **medial plantar nerve** viscoelastic assessment increases with DPN severity and that combining shear wave speed and viscosity improves discrimination between mild and moderate DPN compared with Cs alone but not compared with Vi alone. - Data are not publicly available due to privacy and ethical restrictions. Ethical approval was obtained from the Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine (approval no. CZDSFYLL2026-057-01). ### 17. [VAMHA–MYRHA Combination Improves Menstrual Regularity and Ovulation in PMOS: Randomized Multicentr](https://medichelpline.com/clinical-feed/medrxiv-2-evaluation-of-the-efficacy-and-safety-of-combination-therapy-of-vamha-and-myrha.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [VAMHA–MYRHA Combination Improves Menstrual Regularity and Ovulation in PMOS: Randomized Multicentr](https://medichelpline.com/clinical-feed/medrxiv-2-evaluation-of-the-efficacy-and-safety-of-combination-therapy-of-vamha-and-myrha.md) > **Executive GIST:** - This open-label, randomized, multicentre prospective study compared a combination of **VAMHA and MYRHA** tablets against standard non-hormonal therapy (Metformin 500 mg + Myoinositol 600 mg) in women with polyendocrine metabolic ovarian syndrome (**PMOS**, formerly PCOS). - Seventy-one women were randomized: Group A (VAMHA + MYRHA; n=37) and Group B (Metformin + Myoinositol; n=34). Treatment duration was 180 days with twice-daily dosing in both arms. - Primary outcome assessed restoration of regular menstruation. Significantly more participants in Group A achieved regular cycles (31) than in Group B (22) (p<0.05). - Ovulation rates favored the VAMHA–MYRHA group: 16 participants ovulated in Group A versus 6 in Group B (p<0.05). - Both groups showed significant improvements in menstrual irregularity and related symptoms; both arms also had significant reductions in **Anti-Mullerian Hormone (AMH)**, fasting insulin, and **body mass index (BMI)** (p<0.05). - Resolution of polycystic ovarian morphology on ultrasound occurred in 13 participants (38.23%) in Group A and 10 participants (33.33%) in Group B. - Safety: both therapies were reported as well tolerated with no major safety concerns documented in the manuscript. - Study registration: CTRI/2022/12/048147. Ethics approvals were obtained at the participating centres; informed consent was confirmed. - As a medRxiv preprint, the report has not been peer reviewed; the authors note data are contained in the manuscript and the findings should not yet guide clinical practice. ### 18. [US Trends in GLP-1/GIP Use: Indications, User Profiles, and Access Pathways (Understanding America](https://medichelpline.com/clinical-feed/medrxiv-1-glp-1-gip-uptake-indication-and-access-pathways-among-us-adults-in-the.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [US Trends in GLP-1/GIP Use: Indications, User Profiles, and Access Pathways (Understanding America](https://medichelpline.com/clinical-feed/medrxiv-1-glp-1-gip-uptake-indication-and-access-pathways-among-us-adults-in-the.md) > **Executive GIST:** - This prospective cohort used the nationally representative **Understanding America Study** panel (address-based, ~15,000 adults) with three surveillance waves (March 2024, December 2024, October 2025) to measure real-world uptake, indications, clinical profiles, and access pathways for GLP-1/GIP therapies. - Sample included 9,150 respondents (1,274 reporting any GLP-1/GIP use). Weighted prevalence rose from 8.2% to 12.0% between March 2024 and October 2025, representing an estimated 32 million US adults. - Indication patterns shifted: weight-loss indications increased (from 4.1% to 5.6%) while diabetes-indicated use remained stable (5.3% to 5.4%). Overall, users had a high cardiometabolic burden (obesity 68.2%; diabetes 53.6%), but profiles differed by indication. - Diabetes-indicated users were older (median 59 years) versus weight-loss users (median 49 years). Weight-loss users were more often female (69.9% vs 51.3%) and tended to be healthier on measured characteristics. - Access pathways diversified: about one in three users (≈9 million) obtained GLP-1/GIP through **non-traditional** channels largely invisible to claims data. Among weight-loss-indicated users, 33% reported no conventional prescription, 41% used compounding, online, or foreign pharmacies, and 43% lacked coverage. - Non-traditional users had higher reports of unlisted, likely compounded formulations (19.8% vs 4.1%). These differences were statistically significant (all p < 0.05). - The study incorporated survey-weighted prevalence estimates, sociodemographic and cardiometabolic measures, treatment and access characteristics, and linked smartwatch-derived measures (resting heart rate, heart rate variability, maximal activity heart rate, step count, and sleep metrics) though specific smartwatch results were not detailed in the abstract. - The authors emphasize rapid growth and diversification in real-world **GLP-1/GIP** use and raise concerns about safety, efficacy, and coverage for treatments obtained outside traditional channels. The GLIMMER dataset is public for researchers via the UAS data portal; ethical approval was provided by BRANY IRB. ### 19. [Left ventricular hypertrophy and brain atrophy in type 2 diabetes: findings from the D2 cohort](https://medichelpline.com/clinical-feed/medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Left ventricular hypertrophy and brain atrophy in type 2 diabetes: findings from the D2 cohort](https://medichelpline.com/clinical-feed/medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2.md) > **Executive GIST:** - This multicentre observational Diabetes & Dementia (D2) cohort study assessed brain volume and cognitive trajectories over 2 years in people with **type 2 diabetes mellitus (T2DM)**. Participants underwent baseline and 2-year brain MRI, transthoracic echocardiography (TTE) and cognitive testing. - Recruitment ran from 20 May 2016 to 20 March 2020. Of 2,378 screened, 702 were eligible, 196 consented, 150 completed baseline assessments and 123 completed full 2-year follow-up with complete MRI, TTE and cognitive data (17.4% attrition). - Baseline left ventricular hypertrophy (**LVH**) was associated with female sex, older age, lower education, lower mood, hypertension, obesity, beta-blocker use, and smaller total brain volume (**TBV**). - Participants with baseline cognitive impairment showed greater brain atrophy over 2 years. Lower education, hypertension, and lower baseline cognitive scores predicted cognitive decline. - Using inverse probability of treatment weighting for causal inference and excluding participants with non-positivity on age and baseline TBV, analysis included 62 without LVH and 31 with LVH. The presence of LVH was associated with a **lower TBV change** (standardized mean difference 6.3 cm3, 95% CI 0.1–12.5, P = .048). - LVH had no detectable effect on cognitive decline over 2 years in this cohort. - The authors conclude that LVH-treated patients (for example with beta-blockers) may derive both cardioprotective and neuroprotective benefits, and they note guideline-directed LVH therapies could be relevant. Trial registration and ethics approvals were reported; no competing interests declared. ### 20. [ADA internal review says expulsions were for conduct, denies censoring opinions or calling police](https://medichelpline.com/clinical-feed/stat-news-0-stat-ada-review-of-members-expulsion-denies-group-censored-opinions-called-in.md) - **Source:** STAT News | **Published:** 2026-09-01 - **Detail Markdown URL:** [ADA internal review says expulsions were for conduct, denies censoring opinions or calling police](https://medichelpline.com/clinical-feed/stat-news-0-stat-ada-review-of-members-expulsion-denies-group-censored-opinions-called-in.md) > **Executive GIST:** - An internal five-person committee convened by the **American Diabetes Association** (ADA) reviewed the June 5 incidents at the ADA’s 2026 scientific sessions in New Orleans in which five members were removed for distributing a published commentary. - The commentary in question was an April 29 opinion piece published in **Diabetes Care** criticizing federal funding cuts; copies were distributed outside the hall where the NIH director was scheduled to speak. - The committee’s findings, summarized in an ADA press release, concluded the removals were prompted by the attendees’ behavior and violations of the conference **code of conduct** that restricts distribution of printed materials in certain areas, not by the content of the commentary. - The review explicitly rejected claims that the ADA acted to silence the substance of the editorial or that the organization had called local law enforcement in response to the distribution; those assertions were denied in the committee’s findings. - The committee’s report will be forwarded to the ADA board for potential action, but the press release and review details appear unlikely to end the public controversy that followed the expulsions. - STAT reported the existence of the committee’s findings and their summary; the outlet noted additional material was behind its STAT+ paywall, and some specifics of the review and any board response were not reported in the publicly available source. - The committee grounded its conclusions in the attendees’ conduct in the conference venue rather than the editorial’s content; the ADA’s conference policies prohibit certain distribution activities and were cited in the review. - The review process involved a five-person committee selected by the ADA; beyond that, identities of committee members, the full text of the report, and any proposed remedial actions were not provided in the source. - The controversy traces to a high-profile setting — distribution occurred near an NIH director’s scheduled talk at the ADA scientific sessions — which likely amplified scrutiny and public attention. - The source materials referenced by the committee’s summary include the ADA press release and the Diabetes Care commentary; STAT indicated further details are accessible only to STAT+ subscribers and that the review is being sent to the ADA board for action. ### 21. [Independent review: Disruptions, not censorship, at ADA’s June Scientific Sessions](https://medichelpline.com/clinical-feed/stat-news-1-opinion-diabetes-association-ceo-what-an-independent-review-says-happened-at.md) - **Source:** STAT News | **Published:** 2026-09-01 - **Detail Markdown URL:** [Independent review: Disruptions, not censorship, at ADA’s June Scientific Sessions](https://medichelpline.com/clinical-feed/stat-news-1-opinion-diabetes-association-ceo-what-an-independent-review-says-happened-at.md) > **Executive GIST:** - An independent, volunteer review panel of five investigators examined events at the American Diabetes Association (ADA) Scientific Sessions in New Orleans on June 5 where several attendees were removed after repeated disruptions. - The review found no evidence that the ADA suppressed the viewpoint at issue; the editorial criticized was published in the ADA’s own journal, **Diabetes Care**. - The removals were attributed to attendees’ conduct — repeated disruptions that continued after multiple requests to stop — and therefore violated the conference code of conduct, not the content of distributed material. - The review found no evidence that the ADA called the New Orleans Police Department; security at the event included on-site personnel, some of whom were off-duty police working as event security, not acting as law enforcement. - ADA leadership acknowledged shortcomings in communication by staff and security in the moments before and during the disruption and accepts responsibility for missed opportunities to manage the situation better. - The CEO, Charles “Chuck” Henderson, reiterated the ADA’s long-standing commitment to open debate and to publishing dissenting views, and noted the organization’s history of publicly criticizing federal policy that harms diabetes research and prevention programs. - The CEO emphasized the broader context of anxiety in the research community about proposed federal funding cuts and highlighted ADA advocacy efforts opposing an OMB proposal that would shift grant decision power toward political appointees; he cited recent Senate language blocking that rule from taking effect and ongoing efforts in the House. - The CEO asked the community to focus on the larger policy fight over **research funding**, to hold the ADA accountable where it fell short, and to rebuild trust by pursuing a clear accounting alongside collaborative action against threats to diabetes research. - The review’s release was intended to replace competing narratives with established facts and to support rebuilding trust while maintaining advocacy for the diabetes field. ### 22. [Endocrine Society Urges Congress to Increase NIH Funding to $51.3 Billion](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-advocates-to-increase-nih-funding.md) - **Source:** Endocrine News | **Published:** 2026-09-01 - **Detail Markdown URL:** [Endocrine Society Urges Congress to Increase NIH Funding to $51.3 Billion](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-advocates-to-increase-nih-funding.md) > **Executive GIST:** - The Endocrine Society is participating in the annual **Rally for Medical Research Hill Day** to press Congress for higher federal support for biomedical research. - On September 17, the Society will bring member researchers to Washington, D.C., to join hundreds of organizations, societies, and patient groups to advocate for increased NIH funding. - The Rally for Medical Research is in its fourteenth year and presents a unified request; this year’s specific ask is **$51.3 billion for the NIH**. - The advocacy effort is timed to influence final appropriations work and to underscore the need to pass a **Continuing Resolution (CR)** by September 30 to avoid a government shutdown. - Congress passed a short-term CR to fund the government through December, allowing the House and Senate to complete an appropriations bill during a potential lame-duck session after the midterm elections; reconciliation of CR versions was still required when Congress returned in September. - The Endocrine Society encourages U.S.-based members who cannot attend Hill Day to participate in an online advocacy campaign via the Society’s Take Action page and to click the Rally for Medical Research campaign link. - The article notes the Rally’s historical impact on increasing research funding by coordinating the research community around a single funding request. - Source links and campaign resources are hosted on the Endocrine Society advocacy pages; specific procedural or logistical details for participants were not reported in the source. ### 23. [Usability, Acceptability, and Feasibility of Continuous Glucose Monitoring for Children and Adoles](https://medichelpline.com/clinical-feed/medrxiv-3-usability-acceptability-and-feasibility-of-continuous-glucose-monitoring-among.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-01 - **Detail Markdown URL:** [Usability, Acceptability, and Feasibility of Continuous Glucose Monitoring for Children and Adoles](https://medichelpline.com/clinical-feed/medrxiv-3-usability-acceptability-and-feasibility-of-continuous-glucose-monitoring-among.md) > **Executive GIST:** - This prospective study evaluated the **usability**, **acceptability**, and **feasibility** of continuous glucose monitoring (**CGM**) among children and adolescents with **type 1 diabetes** at Kenyatta National Hospital in Kenya. - Participants were aged 4–25 years, had at least six months of prior T1D management, and included caregivers of those under 18. - Forty young people with T1D used CGM for three months in place of self-monitoring of blood glucose (SMBG). - Standardized instruments were administered: the System Usability Scale (SUS), a Theoretical Framework of Acceptability questionnaire, the Diabetes Distress Scale (DDS), the Glucose Monitoring Satisfaction Survey (GMSS), and a feasibility survey. - Median SUS score was very high at 98.8 (IQR 92.5–100.0), indicating excellent perceived usability. - Acceptability was reported as high; median total GMSS improved from 3.73 at baseline to 4.73 after three months. - Among adolescents and adults overall DDS median decreased from 1.54 to 1.36, with reductions in most distress domains except hypoglycemia distress which increased; physician distress remained low. - For caregivers, median DDS declined from 2.05 (moderate distress) to 1.90 (low distress), with modest reductions in teen management and parent-teen relationship distress and a slight increase in personal distress. - Median CGM active wear time during the study was 89%, supporting feasibility of sustained device use over the three-month period. - Authors conclude findings support integrating **CGM** into routine diabetes management in low-resource settings, while noting the short follow-up may not capture long-term adherence or changing perceptions. - Ethical approval was obtained from Kenyatta National Hospital–University of Nairobi Ethics and Research Committee; data access is restricted by that committee and available on application. Funding came from FIND with a grant from the Helmsley Charitable Trust. No competing interests were declared. ### 24. [Omnipod 5 Automated Insulin Delivery: 12-Month Extension Outcomes in Adults with Type 1 Diabetes](https://medichelpline.com/clinical-feed/pubmed-42671087.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-01 | DOI: [10.1002/edm2.70321](https://doi.org/10.1002%2Fedm2.70321) - **Detail Markdown URL:** [Omnipod 5 Automated Insulin Delivery: 12-Month Extension Outcomes in Adults with Type 1 Diabetes](https://medichelpline.com/clinical-feed/pubmed-42671087.md) > **Executive GIST:** - The 12-month extension followed a multicenter randomized controlled trial (RCT) evaluating the **Omnipod 5** Automated Insulin Delivery (AID) System in adults with **Type 1 diabetes** in France. Participants had previously used either AID or standard non-automated pump therapy for 13 weeks in the parent RCT. - Seventy-six participants in France were eligible to transition to or continue with AID; 75 enrolled in the extension phase. The extension compared glycemic, safety, and psychosocial outcomes to RCT baseline or end of RCT as appropriate. - From RCT baseline to the end of the 12-month extension, **time in range (70–180 mg/dL)** increased by 17.9 percentage points (p 180 mg/dL) decreased by 17.7 percentage points and mean sensor glucose fell by 27.8 mg/dL (both p < 0.0001). HbA1c declined from 8.33% to 7.18% (–1.14%; p < 0.0001). - Glycemic improvements were sustained both for participants who continued AID from the RCT intervention arm and for those who transitioned from standard therapy to AID during the extension. - Diabetes Quality of Life–brief scores and Hypoglycemia Confidence Scale scores were maintained or improved at 6 and 12 months compared with RCT baseline. - Adverse events were infrequent, reported as 12 events per 100 person-years during the extension phase. - The authors conclude the extension supports the parent RCT findings, demonstrating safety and sustained glycemic and psychosocial benefits of the Omnipod 5 System in adults with T1D over 12 months in France. Trial registration: ClinicalTrials.gov NCT05409131. ### 25. [Thyroid Function and MAFLD in Type 2 Diabetes: Case-Control Study of FT3 and TSH Associations](https://medichelpline.com/clinical-feed/pubmed-42664128.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-01 | DOI: [10.7417/CT.2026.2108](https://doi.org/10.7417%2FCT.2026.2108) - **Detail Markdown URL:** [Thyroid Function and MAFLD in Type 2 Diabetes: Case-Control Study of FT3 and TSH Associations](https://medichelpline.com/clinical-feed/pubmed-42664128.md) > **Executive GIST:** - Metabolic dysfunction-associated fatty liver disease (**MAFLD**) is common in patients with **type 2 diabetes mellitus (T2DM)** and is linked to insulin resistance and dyslipidemia. - This case-control study enrolled 150 patients with T2DM: 75 with MAFLD and 75 without MAFLD. - Hepatic steatosis was diagnosed using transient elastography with the controlled attenuation parameter (**CAP**). - Serum thyroid tests measured included **free triiodothyronine (FT3)**, **free thyroxine (FT4)**, and **thyroid-stimulating hormone (TSH)**, using chemiluminescent immunoassays. - Patients with MAFLD had significantly lower **FT3** and higher **TSH** compared with diabetic controls without MAFLD (p = 0.016 and p < 0.001, respectively); **FT4** did not differ between groups. - MAFLD cases demonstrated an adverse metabolic profile with higher triglycerides, total cholesterol, and LDL cholesterol and lower HDL cholesterol (all p < 0.001). - Liver enzymes were reported as significantly different between groups in the abstract, but the specific enzyme values and statistics were not fully provided in the source text. - Multivariate logistic regression was used to identify independent predictors of MAFLD, but the abstract truncates before reporting which variables remained independent predictors. - The findings suggest an association between altered thyroid function—specifically lower FT3 and higher TSH—and MAFLD in people with T2DM, with implications for metabolic risk characterization. - Several methodological details and full result data (exact liver enzyme levels, regression model outputs, and effect sizes) were not reported in the provided source excerpt. ### 26. [Lifecourse Mendelian randomization: childhood vs adulthood adiposity and later-life sleep outcomes](https://medichelpline.com/clinical-feed/medrxiv-3-investigating-adiposity-in-childhood-and-adulthood-on-later-life-sleep-health-a.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-31 - **Detail Markdown URL:** [Lifecourse Mendelian randomization: childhood vs adulthood adiposity and later-life sleep outcomes](https://medichelpline.com/clinical-feed/medrxiv-3-investigating-adiposity-in-childhood-and-adulthood-on-later-life-sleep-health-a.md) > **Executive GIST:** - This preprint used two-sample **Mendelian randomization** to test effects of genetically predicted **childhood adiposity** and **adulthood adiposity** on later-life sleep traits: insomnia, morning chronotype, sleep duration, daytime sleepiness and daytime napping. - Genetic instruments came from GWAS of UK Biobank body size (n=453,169) and large consortia for obstructive sleep apnea (OSA; Million Veteran Program, n=410,268), insomnia and chronotype (23andMe datasets; combined sample sizes reported in source). - Univariable MR found no evidence that genetically predicted childhood adiposity increased later-life **insomnia** risk (OR 0.94, 95% CI 0.87–1.03). - Multivariable MR adjusting for adulthood adiposity provided evidence of a direct *protective* effect of higher childhood body size on later-life insomnia (OR 0.70, 95% CI 0.64–0.77). - Both univariable and multivariable MR indicated a positive effect of increased childhood body size on being a **morning chronotype** (univariable OR 1.16, 95% CI 1.01–1.33; multivariable OR 1.36, 95% CI 1.15–1.62) after accounting for adulthood body size. - Adjusting additionally for **OSA** did not materially change those childhood adiposity estimates in the analyses reported. - Both childhood and adulthood adiposity were associated with **OSA**, and OSA was associated with insomnia in the reported analyses. - Increased adulthood body size increased risk of **insomnia** and of being a **morning chronotype** in both univariable and multivariable analyses. - Authors conclude that higher childhood adiposity is not a risk factor for later-life insomnia when adulthood adiposity is considered; if a healthy adult body size is maintained, higher childhood adiposity may reduce insomnia risk and increase likelihood of morningness in later life. - Data access statements and ethics approvals are reported: GWAS summary data available on request to UK Biobank, OSA data via MVP application, and insomnia/chronotype data from 23andMe on request. Competing interest: one author employed by GlaxoSmithKline; others report no competing interests. ### 27. [Hormone oscillations maintain cellular responsiveness to future physiological demands](https://medichelpline.com/clinical-feed/biorxiv-1-hormone-oscillations-preserve-cellular-responsiveness-to-future-physiological.md) - **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-08-31 - **Detail Markdown URL:** [Hormone oscillations maintain cellular responsiveness to future physiological demands](https://medichelpline.com/clinical-feed/biorxiv-1-hormone-oscillations-preserve-cellular-responsiveness-to-future-physiological.md) > **Executive GIST:** - Living organisms must sense and adapt to changing physiological demands while avoiding overstimulation; continuous hormone exposure can desensitize signaling pathways and blunt future responses. - The authors investigated how cells preserve responsiveness despite protective desensitization, using **epinephrine** as a model hormonal mediator of stress. - They compared oscillatory (ultradian) hormone patterns with constant hormone exposure and found that **hormone oscillations** enabled **receptor resensitization** when hormone levels fell, whereas constant stimulation did not. - Oscillatory hormone delivery preserved cellular “alertness” to subsequent stress and maintained tunability of responses across different stimulus intensities. - Oscillations also supported coordination across diverse cell types by more consistently maintaining responsiveness across a range of hormone concentrations and receptor kinetic parameters. - The authors propose that oscillatory endocrine signaling provides a general strategy for balancing protective desensitization with preservation of responsiveness to future physiological demands. - The study used epinephrine as the exemplar ligand; specific experimental details, quantitative data, and methods are reported in the original preprint. - The authors declared no competing interests and acknowledged support from the G. Harold & Leila Y. Mathers Foundation and the European Molecular Biology Organization. ### 28. [Population-based retrospective cohorts to validate algorithms and estimate prevalence of T1D, T2D](https://medichelpline.com/clinical-feed/bmj-open-1-retrospective-population-based-cohorts-for-assessing-the-performance-of.md) - **Source:** BMJ Open | **Published:** 2026-08-31 - **Detail Markdown URL:** [Population-based retrospective cohorts to validate algorithms and estimate prevalence of T1D, T2D](https://medichelpline.com/clinical-feed/bmj-open-1-retrospective-population-based-cohorts-for-assessing-the-performance-of.md) > **Executive GIST:** - The study is a retrospective, longitudinal population-based protocol in Quebec covering 1997–2027 to evaluate diabetes subtype classification and quantify phenotype burden. - It highlights that **type 2 diabetes (T2D)** comprises most global diabetes but **type 1 diabetes (T1D)**, **latent autoimmune diabetes in adults (LADA)** and other specific types are under-recognised. - No existing population-based prevalence or incidence estimates by diabetes phenotype are available for Quebec; current medico-administrative algorithms do not reliably distinguish subtypes. - Phase 1 will assess diagnostic performance of the Corsenac et al. (2022) medico-administrative algorithms across four phenotypes (T1D, T2D, LADA, others) using three independent reference subsamples within a cohort (A1–A2–A3; n = 5,200). - Subsamples: A1 = self-reported T1D and LADA; A2 = physician-confirmed T2D and other specific types; A3 = general population respondents reporting diabetes status and phenotype when applicable. - Records from A1–A3 will be probabilistically linked to medico-administrative and pharmaceutical claims from the **RAMQ** by the Institut de la statistique du Québec (ISQ). - Machine learning methods will be used to refine algorithmic definitions for the four phenotypes based on linked data and reference subsamples. - Phase 2 will apply refined algorithms to a second medico-administrative, population-based cohort C (n = 50,000) to produce simultaneous prevalence and incidence estimates for the four phenotypes. - Analyses are limited to individuals continuously covered by RAMQ's public drug insurance, which provides pharmaceutical data and covers about 46% of Quebec's population. - Statistical reweighting — calibration on population margins (phase 1) and standardised inverse probability weighting (phase 2) — will adjust performance metrics and frequency estimates to represent the general Quebec population. - Ethics approvals from partner institutions confirmed feasibility; the study is registered on ClinicalTrials.gov (NCT06573905). Results will be disseminated via scientific and public health channels. ### 29. [Arterial stiffness linked to choroidal vascular changes in type 2 diabetes, strongest at ages 30–50](https://medichelpline.com/clinical-feed/pubmed-42671635.md) - **Source:** PubMed / NCBI | **Published:** 2026-08-31 | DOI: [10.1007/s10792-026-04214-4](https://doi.org/10.1007%2Fs10792-026-04214-4) - **Detail Markdown URL:** [Arterial stiffness linked to choroidal vascular changes in type 2 diabetes, strongest at ages 30–50](https://medichelpline.com/clinical-feed/pubmed-42671635.md) > **Executive GIST:** - This study evaluated associations between systemic arterial stiffness and choroidal vascular structure in patients with **type 2 diabetes** using wide-field optical coherence tomography angiography (OCTA). - The cohort included 177 eyes from 95 T2D patients who underwent clinical assessment and 24 × 20 mm OCTA imaging. - Three-dimensional choroidal parameters were calculated on a 12 × 12 mm fovea-centered grid: **choroidal vessel volume (CVV)**, stromal volume (CSV), and choroidal vascularity index (CVI). Two-dimensional vascular density measures were also obtained for multiple layers. - Systemic arterial stiffness was measured by **brachial-ankle pulse wave velocity (baPWV)**. Correlation and regression analyses examined relationships overall, with age-adjusted and age-stratified models. - CVV and CSV showed significant negative correlations with both age and baPWV (p < 0.05) in most regional comparisons; two-dimensional OCTA vascular measures did not show the same reduction patterns. - After adjusting for age, the correlations between baPWV and choroidal volumes lost statistical significance in the full cohort. - Age-stratified analysis identified a clear linear negative association between baPWV and both CVV and CSV among patients aged 30–50 years (p < 0.05 in most regions), with maximum regression coefficients of approximately -0.14 for CVV and -0.25 for CSV. - The authors conclude that three-dimensional choroidal parameters (CVV and CSV) may serve as biomarkers of systemic vascular health in T2D, particularly for the 30–50 year age group. - Conflict of interest: none declared. Ethical approval: institutional board granted exemption for retrospective anonymized data (Exemption No. 24412-4-01). ### 30. [Multi-omics Gene Prioritization Identifies MCM6 and Five Causal Genes in Polycystic Ovary Syndrome](https://medichelpline.com/clinical-feed/pubmed-42600058.md) - **Source:** PubMed / NCBI | **Published:** 2026-08-31 | DOI: [10.1096/fj.202601567R](https://doi.org/10.1096%2Ffj.202601567R) - **Detail Markdown URL:** [Multi-omics Gene Prioritization Identifies MCM6 and Five Causal Genes in Polycystic Ovary Syndrome](https://medichelpline.com/clinical-feed/pubmed-42600058.md) > **Executive GIST:** - The study used an integrative **multi-omics** pipeline to prioritize candidate genes for **polycystic ovary syndrome (PCOS)** by combining cross-tissue and tissue-specific transcriptome-wide association studies (TWAS), gene-based association testing, causal inference, network analysis, chemical‑gene interactions, PheWAS, and expression profiling. - Primary genetic inputs included the FinnGen R12 GWAS dataset and GTEx v8 eQTLs for TWAS; external validation used a PCOS meta-analysis of Rotterdam- and NIH-criteria cohorts and UK Biobank summary statistics. - Cross-tissue (UTMOST) and tissue-specific (FUSION) TWAS results were integrated with MAGMA gene-based association testing to nominate high-confidence candidate genes. - Causal inference approaches applied to prioritized genes included **Mendelian randomization (MR)**, colocalization analysis, summary data–based MR, and the HEIDI test; six genes showed evidence of causal association with PCOS risk. - A total of 15 candidate genes were prioritized; **MCM6** was supported by all three prioritization approaches, while the other 14 had support from two approaches. - The six genes with evidence of causal association were MCM6, CERS5, DNM3, LIMA1, MST1R, and NR1H3 (identified in figures and network analyses). - GeneMANIA network analysis linked prioritized genes to biological processes such as DNA replication and repair, cell cycle regulation, nucleic-acid enzyme activities, chromosomal structure, reproductive system development, and sex differentiation. - Gene-chemical-disease analysis suggested these genes may mediate interactions between genetic risk for PCOS and environmental or metabolic factors. - Phenome-wide association study (PheWAS) results indicated pleiotropy: the candidate genes associate with PCOS-related traits, including metabolic and cardiovascular phenotypes. - Transcriptomic data from GEO demonstrated downregulated **MCM6** expression in granulosa cells from PCOS patients. - External validation across independent datasets showed limited consistency, likely reflecting differences in statistical power and cohort heterogeneity. - The authors present a multipronged pipeline for prioritizing PCOS genes and provide novel insights into the genetic architecture and potential biological pathways involved in PCOS. ## Machine-Readable Pagination & Traversal - [← Main Clinical Feed Hub](https://medichelpline.com/clinical-feed.md) - [Next Page (Page 2) →](https://medichelpline.com/clinical-feed/endocrinology.md?page=2) ## Other Clinical Specialties - [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md) - [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md) - [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md) - [Oncology](https://medichelpline.com/clinical-feed/oncology.md) - [Neurology](https://medichelpline.com/clinical-feed/neurology.md) - [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) - [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md) - [Dentistry](https://medichelpline.com/clinical-feed/dentistry.md) - [Public Health](https://medichelpline.com/clinical-feed/public-health.md) - [Regulatory & FDA](https://medichelpline.com/clinical-feed/regulatory.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.